Literature DB >> 20048723

Management of antiretroviral failure and resistance in developing countries.

Claudia Hawkins1, Robert L Murphy.   

Abstract

PURPOSE OF REVIEW: As scale-up of antiretroviral therapy in developing countries continues, an increasing number of patients developing antiretroviral failure and resistance are being identified. This review focuses on the identification and management of these complex patients in settings with limited antiretroviral drug options and resources. RECENT
FINDINGS: The number of patients receiving second-line and salvage therapies remains lower than the number of patients who are eligible for these therapies. This situation is a result of delays in the recognition and management of antiretroviral failure caused by a lack of sensitive diagnostic techniques, and effective and tolerable alternative antiretroviral drugs. Alternative treatment options using currently available therapies in developing countries are suggested for the management of patients with antiretroviral failure and resistance. Strategies to enhance the durability of antiretroviral regimens to minimize the risk of failure are also discussed.
SUMMARY: The development of antiretroviral failure and drug resistance among HIV-infected patients in developing countries is of increasing concern. Intensive efforts by HIV care and treatment programs are required to ensure the timely and effective diagnosis and management of these patients. Efforts to minimize the risk of failure are also needed given the significant cost and resource limitations in these settings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20048723     DOI: 10.1097/COH.0b013e328331d2fb

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  8 in total

1.  HIV load testing with small samples of whole blood.

Authors:  Katrin Steinmetzer; Thomas Seidel; Andreas Stallmach; Eugen Ermantraut
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Authors:  Ronald S Veazey; Thomas J Ketas; Jason Dufour; Terri Moroney-Rasmussen; Linda C Green; P J Klasse; John P Moore
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

3.  Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.

Authors:  Victoria Johnston; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

4.  Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Kathryn Anastos; Stephen J Gange; Howard Minkoff; Mary Young; Joel Milam; Mardge H Cohen; Gerald B Sharp; Yong Huang; Ruth M Greenblatt
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

5.  Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network.

Authors:  Marcelo Wolff; Bryan E Shepherd; Claudia Cortés; Peter Rebeiro; Carina Cesar; Sandra Wagner Cardoso; Jean W Pape; Denis Padgett; Juan Sierra-Madero; Juan Echevarria; Catherine C McGowan
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

6.  HIV Wasting Syndrome in a Nigerian Failing Antiretroviral Therapy: A Case Report and Review of the Literature.

Authors:  Dimie Ogoina; Reginald O Obiako; Haruna M Muktar
Journal:  Case Rep Med       Date:  2010-12-27

7.  Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil--1996-2012.

Authors:  Unaí Tupinambás; Helena Duani; Ana Virgínia Cunha Martins; Agdemir Waleria Aleixo; Dirceu Bartolomeu Greco
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-06       Impact factor: 2.743

8.  Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.

Authors:  Marianne Harris; Bohdan Nosyk; Richard Harrigan; Viviane Dias Lima; Calvin Cohen; Julio Montaner
Journal:  AIDS Res Treat       Date:  2012-11-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.